title: Electroporation-mediated administration of candidate DNA vaccines against HIV-1.
abstract: Vaccines to prevent HIV remain desperately needed, but a number of challenges, including retroviral integration, establishment of anatomic reservoir sites, high sequence diversity, and heavy envelope glycosylation. have precluded development of a highly effective vaccine. DNA vaccines have been utilized as candidate HIV vaccines because of their ability to generate cellular and humoral immune responses, the lack of anti-vector response allowing for repeat administration, and their ability to prime the response to viral-vectored vaccines. Because the HIV epidemic has disproportionately affected the developing world, the favorable thermostability profile and relative ease and low cost of manufacture of DNA vaccines offer additional advantages. In vivo electroporation (EP) has been utilized to improve immune responses to DNA vaccines as candidate HIV-1 vaccines in standalone or prime-boost regimens with both proteins and viral-vectored vaccines in several animal models and, more recently, in human clinical trials. This chapter describes the preclinical and clinical development of candidate DNA vaccines for HIV-1 delivered by EP, including challenges to bringing this technology to the developing world.
authors: Department of Retrovirology, US Army Medical Component, Armed Forces Research Institute of Medical Sciences (AFRIMS), Bangkok, Thailand.
authors: Sandhya
authors: S
authors: Vasan
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology* / Q000378:metabolism*; D000818:Animals; D002986:Clinical Trials as Topic; D018274:Electroporation / Q000379:methods*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D019444:Vaccines, DNA / Q000276:immunology* / Q000378:metabolism*
chemical_list: D016915:AIDS Vaccines; D019444:Vaccines, DNA